PHI-501, a novel pan-RAF/DDRs dual kinase inhibitor, overcomes BRAF or MEK inhibitor resistance in melanoma

被引：0
|
作者：
Kim, Sue Min
Park, Jung Hee
Nam, Ky-Youb
Han, June H-J
Kim, Kyu-Tae
Yoon, Jeong Hyeok
Sengupta, Sandip
Sim, Taebo
Shin, Sang Joon
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-411
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
411
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Palbociclib synergizes with BRAF and MEK inhibitors in treatment naive melanoma but not after the development of BRAF inhibitor resistance
    Martin, Claire A.
    Cullinane, Carleen
    Kirby, Laura
    Abuhammad, Shatha
    Lelliott, Emily J.
    Waldeck, Kelly
    Young, Richard J.
    Brajanovski, Natalie
    Cameron, Donald P.
    Walker, Rachael
    Sanij, Elaine
    Poortinga, Gretchen
    Hannan, Ross D.
    Pearson, Richard B.
    Hicks, Rodney J.
    McArthur, Grant A.
    Sheppard, Karen E.
    INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (10) : 2139 - 2152
  • [32] Targeting of the Lipid Metabolism Impairs Resistance to BRAF Kinase Inhibitor in Melanoma
    Vergani, Elisabetta
    Beretta, Giovanni L.
    Aloisi, Mariachiara
    Costantino, Matteo
    Corno, Cristina
    Frigerio, Simona
    Tinelli, Stella
    Dugo, Matteo
    Accattatis, Felice Maria
    Granata, Agnese
    Arnaboldi, Lorenzo
    Rodolfo, Monica
    Perego, Paola
    Gatti, Laura
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 10
  • [33] Global trends and emerging insights in BRAF and MEK inhibitor resistance in melanoma: a bibliometric analysis
    Bai, Jianhao
    Wan, Zhongqi
    Zhou, Wanru
    Wang, Lijun
    Lou, Wei
    Zhang, Yao
    Jin, Haiying
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2025, 12
  • [34] Exarafenib (KIN-2787) is a potent, selective pan-RAF inhibitor with activity in preclinical models of BRAF class II/III mutant and NRAS mutant melanoma
    Wang, Tim S.
    Lee, Catherine
    Severson, Paul
    Pelham, Robert J.
    Williams, Richard
    Miller, Nichol L. G.
    CANCER RESEARCH, 2023, 83 (07)
  • [35] Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic BRAF Mutation
    Miyauchi, Shunsaku
    Shien, Kazuhiko
    Takeda, Tatsuaki
    Araki, Kota
    Nakata, Kentaro
    Miura, Akihiro
    Takahashi, Yuta
    Kurihara, Eisuke
    Ogoshi, Yusuke
    Namba, Kei
    Suzawa, Ken
    Yamamoto, Hiromasa
    Okazaki, Mikio
    Soh, Junichi
    Tomida, Shuta
    Yamane, Masaomi
    Sakaguchi, Masakiyo
    Toyooka, Shinichi
    ANTICANCER RESEARCH, 2020, 40 (05) : 2667 - 2673
  • [36] Development of a dual inhibitor of pan-RAF and angiogenesis for the treatment of metastatic colorectal cancer with mutant K-RAS
    Hong, Sungpyo
    Choi, Younghoon
    Kwon, Ho-Seok
    Park, Yong Bin
    Ki, Min-Hyo
    Shin, Hee Jong
    Lee, Michael
    Ahn, Soon Kil
    CANCER RESEARCH, 2017, 77
  • [37] Novel oncogenic BRaf deletions functioning as BRaf homodimer and sensitive to inhibition by LY3009120, a pan Raf and Raf dimer inhibitor
    Chen, Shih-Hsun
    Buchanan, Sean
    Zhang, Youyan
    Van Horn, Robert
    Yin, Tinggui
    Yadav, Vipin
    Wong, Swee Seong
    Huber, Lysiane
    Henry, James
    Conti, Ilaria
    Starling, James J.
    Plowman, Gregory D.
    Peng, Sheng-Bin
    CANCER RESEARCH, 2015, 75
  • [38] Antitumor activity of KIN-2787, a next-generation pan-RAF inhibitor, in preclinical models of human RAF/RAS mutant melanoma
    Miller, Nichol L. G.
    Wang, Tim S.
    Severson, Paul
    Jiang, Ping
    Perez, Michelle
    Timple, Noel
    Kanouni, Toufike
    Franovic, Aleksandra
    Martin, Eric S.
    Murphy, Eric
    CANCER RESEARCH, 2022, 82 (12)
  • [39] Evaluation of Pan-RAF Inhibitor LY3009120 on Human Uveal Melanoma Cell Line 92-1
    Gao, Yu
    Wendt, Sophia
    Krohn, Saskia
    Alammar, Moosheer
    Junghanss, Christian
    Nolte, Ingo
    Escobar, Hugo Murua
    ANTICANCER RESEARCH, 2024, 44 (09) : 3843 - 3848
  • [40] Icariside II overcomes BRAF inhibitor resistance in melanoma by inducing ROS production and inhibiting MITF
    Liu, Xiao
    Li, Zheng
    Li, Ming
    Chai, Jingxiu
    He, Shan
    Wu, Jinfeng
    Xu, Jinhua
    ONCOLOGY REPORTS, 2020, 44 (01) : 360 - 370
12345